Cambridge Epigenetix

Our starting point is TrueMethylTM oxidative bisulfite sequencing (oxBS-Seq), a novel technology that pioneers quantitative, single-base resolution sequencing of the modified bases hydroxymethyl cytosine (5-hmC) and methylcytosine (5-mC). TrueMethyl enables analysis of the DNA methylome with unprecdented accuracy and opens new avenues for basic research, pharmaceutical discovery and diagnostics. Recent studies have shown that at some sites in the genome the level of 5-hmC can be comparable to the level of 5-mC, emphasizing the importance of identifying these variants accurately. However, traditional bisulfite sequencing cannot discriminate between 5-hmC and 5-mC. Co-invented by Prof. Shankar Balasubramanian, who previously co-invented the Solexa / Illumina sequencing-by-synthesis platform, and Michael Booth, innovative oxBS-Seq technology utilises a selective chemical oxidation that accurately distinguishes between 5-mC and 5-hmC. TrueMethyl can be used with a variety of common platforms including next generation sequencing systems, methylation arrays, and targeted assays. Employing chemical oxidation gives very high conversion efficiencies and minimises sequence context effects, giving results of unparalleled quality. TrueMethyl enables: Quantitative measurement of 5-hmC and 5-mC in parallel Single-base resolution methylation and hydroxymethylation analysis Confirmation of the location of unmethylated cytosines CEGX is funded by Syncona Partners as well as Cambridge Enterprise and our management team comprises industry leaders and epigenetics expertise.
Company Growth (employees)
Type
Private
HQ
Great Shelford, GB
Founded
2012
Size (employees)
30 (est)+4%
Cambridge Epigenetix was founded in 2012 and is headquartered in Great Shelford, GB

Key People at Cambridge Epigenetix

Shankar Balasubramian

Shankar Balasubramian

Co-Founder and Director
Jason Mellad

Jason Mellad

Business Development Manager
Mike Booth

Mike Booth

Research Scientist

Cambridge Epigenetix Office Locations

Cambridge Epigenetix has an office in Great Shelford
Great Shelford, GB (HQ)
Focus School - Cambridge Campus

Cambridge Epigenetix Data and Metrics

Summary Metrics

Founding Date

2012

Total Funding

$26.5 m

Latest funding size

$21 m

Time since last funding

over 1 year

Investors

Cambridge Epigenetix's latest funding round in March 2016 was reported to be $21 m. In total, Cambridge Epigenetix has raised $26.5 m

Cambridge Epigenetix Financial Metrics

GBP

Cash (30-Sep-2015)

967.3 k
GBPFY, 2013FY, 2014FY, 2015

Cash

202.3 k1.5 m967.3 k

Accounts Receivable

77.3 k1.7 m243.1 k

Current Assets

336.5 k3.3 m1.3 m

PP&E

3.3 k94 k130.8 k
Y, 2015

Financial Leverage

1.3 x
Show all financial metrics

Traffic Overview of Cambridge Epigenetix

Cambridge Epigenetix Online and Social Media Presence

Cambridge Epigenetix News and Updates

The VC arm of Google’s parent company is betting its billions on life-enhancing healthcare startups (GOOG)

GV is the venture capital arm of Google's parent company Alphabet, and used to be called Google Ventures. The investment firm has backed over 50 healthcare and life science startups looking to reduce human suffering and help people live longer. The size of GV's cheques rang…

SpyBiotech, which makes a ‘superglue’ for vaccines, raises £4M from GV and Oxford

 The startup bug has hit the world of biotechnology, and the latest victim is a business that is building a “super glue” — coincidentally, for bug-combatting vaccines. SpyBiotech — a startup spun out of Oxford University that has developed way to bond antigens to viruses and other particles to make …

Google's venture capital arm has backed a startup spun out of Oxford that is developing 'biotech superglue' (GOOG)

LONDON — Google's venture capital arm has taken part in a £4 million investment round in a startup spun out of Oxford University that is trying to use "biotech superglue" to create new vaccines. GV, formerly Google Ventures, is backing SpyBiotech, which is trying to commerci…

Cambridge Epigenetix Company Life and Culture

You may also be interested in